DAM
CRL icon

Deimos Asset Management’s Charles River Laboratories CRL Stock Holding History

Deimos Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16,640
Closed -$1.37M – 15
2016
Q2 		$1.37M Buy
16,640
+1,640
+11% +$135K 0.6% 34
2016
Q1 		$1.14M Buy
15,000
+5,000
+50% +$370K 0.84% 32
2015
Q4 		$804K Buy
+10,000
New +$721K 0.49% 87

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deimos Asset Management's CRL Position: Q3 2016 in Review

Deimos Asset Management sold out of Charles River Laboratories (CRL) in Q3 2016, closing a stake of 16,640 shares — an estimated $1.37M sold.

Deimos Asset Management first reported a position in CRL in Q4 2015 and held it in 3 quarters. The position peaked at $1.37M in Q2 2016. 283 funds tracked by Wall St. Rank hold CRL as of Q3 2016.

  • Deimos Asset Management reported no remaining Charles River Laboratories position as of Q3 2016 after selling out during the quarter.
  • Deimos Asset Management sold 16,640 Charles River Laboratories shares in Q3 2016, an estimated $1.37M.
  • Deimos Asset Management first reported a position in Charles River Laboratories in Q4 2015 and held it in 3 quarters.
  • Deimos Asset Management's Charles River Laboratories position peaked at $1.37M in Q2 2016.
  • 283 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2016.

Based on Deimos Asset Management's 13F filing for Q3 2016.